Winners and wishers: 8 potential Bay Area drug approvals coming this year
Protagonist (Nasdaq: PTGX) is one of a handful of Bay Area drug developers ready to ask the Food and Drug Administration to ...
Soleno Therapeutics price target raised to $100 from $70 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Soleno Therapeutics (SLNO) to $100 from $70 and keeps a Buy rating on the shares after the ...
Soleno Therapeutics (NASDAQ:SLNO) Sees Strong Trading Volume Following Analyst Upgrade
Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) saw unusually-high trading volume on Monday after HC ...
Soleno Therapeutics (SLNO) Receives a Buy from Piper Sandler
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Soleno Therapeutics (SLNO – Research Report) today and set a price target of ...
Investor's Business Daily on MSN6d
Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower
Soleno Therapeutics won approval for a drug that treats excessive hunger associated with a rare disease, and the biotech ...
TipRanks on MSN3d
Soleno Therapeutics Stock (SLNO) Surges on FDA Green Light for PWS Treatment
Soleno Therapeutics ($SLNO) stock skyrocketed up over 42% this past week on news that it has achieved a significant milestone ...
News-Medical.Net on MSN5h
US FDA approves first treatment for hyperphagia in Prader-Willi syndrome
The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).
Tiny Silicon Valley drugmaker soars on FDA win to treat never-ending hunger
Shares of the Redwood City-based Soleno Therapeutics climbed 38% — the biggest one-day gain since September 2023 — to their ...
STAT6d
Soleno Therapeutics’ ‘life-changing’ rare-disease drug approved
The FDA Wednesday approved the first drug to treat people with Prader-Willi syndrome, a rare genetic disease that causes an ...
American Association of Individual Investors6d
Why Soleno Therapeutics, Inc.’s (SLNO) Stock Is Up 35.80%
Soleno Therapeutics, Inc.’s SLNO share price has surged by 35.80%, which has investors questioning if this is right time to ...
Soleno Therapeutics: In No Rush To Join Buying Frenzy Despite Vykat Approval
Soleno Therapeutics stock has surged over 1,500% since September 2023, driven by the progress and today's FDA approval of ...
Soleno Therapeutics (NASDAQ:SLNO) Trading Up 3.9% Following Analyst Upgrade
Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) shares were up 3.9% during trading on Friday after Stifel Nicolaus ...